1,100 results

#186052-AAV8

Ready-to-use AAV8 particles produced from pZac2.1 gfaABC1D-cyto-GCaMP8s (#186052). In addition to the viral particles, you will also receive purified pZac2.1 gfaABC1D-cyto-GCaMP8s plasmid DNA. gfaABC1D-driven expression of GCaMP8s, localized to the cystosol. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Aug. 6, 2025

Academic Institutions and Nonprofits only

#135429-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-Flex-Axon-EGFP (#135429). In addition to the viral particles, you will also receive purified pAAV-hSyn-Flex-Axon-EGFP plasmid DNA. Syn-driven, Cre-dependent expression of axon-targeted EGFP control. These AAV preparations are suitable purity for injection into animals.

Rylan Larsen

March 19, 2021

Academic Institutions and Nonprofits only

#176750-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV-CamKIIa-jGCaMP8f-WPRE (#176750). In addition to the viral particles, you will also receive purified AAV-CamKIIa-jGCaMP8f-WPRE plasmid DNA. CamKIIa-driven expression of calcium sensor GCaMP8f. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Loren Looger

July 21, 2023

Academic Institutions and Nonprofits only

#26969-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-hChR2(H134R)-EYFP (#26969). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-EYFP plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Lee et al Nature. 2010 Jun 10. 465(7299):788-92.

Feb. 14, 2018

Academic Institutions and Nonprofits only

#26966-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.

March 27, 2024

Academic Institutions and Nonprofits only

#178329-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSyn.iGluSnFR3.v857.PDGFR (#178329). In addition to the viral particles, you will also receive purified pAAV.hSyn.iGluSnFR3.v857.PDGFR plasmid DNA. Synapsin-driven, third generation glutamate sensor iGluSnFR3, variant 857. These AAV preparations are suitable purity for injection into animals.

Kaspar Podgorski

Aggarwal et al Nat Methods. 2023 May 4. doi: 10.1038/s4

May 16, 2023

Academic Institutions and Nonprofits only

#55634-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-mCherry-IRES-Flpo (#55634). In addition to the viral particles, you will also receive purified pAAV-EF1a-mCherry-IRES-Flpo plasmid DNA. EF1a-driven mCherry and bicistronic Flp recombinase expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

May 31, 2019

Academic Institutions and Nonprofits only

#140558-AAV9

Ready-to-use AAV9 particles produced from pAAV-hsyn-GRAB_rDA-mut (#140558). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_rDA-mut plasmid DNA. Synapsin-driven expression of control red fluorescent dopamine sensor GRAB_rDA-mut (does not respond to DA). These AAV preparations are suitable purity for injection into animals.

Yulong Li

Sun et al Nat Methods. 2020 Nov;17(11):1156-1166.

Aug. 31, 2021

Academic Institutions and Nonprofits only

#51507-AAV5

Ready-to-use AAV5 particles produced from AAV pmSyn1-EBFP-Cre (#51507). In addition to the viral particles, you will also receive purified AAV pmSyn1-EBFP-Cre plasmid DNA. EBFP-Cre expression under a human synapsin1 promoter. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Madisen et al Neuron. 2015 Mar 4;85(5):942-58. doi: 10

Oct. 30, 2017

Academic Institutions and Nonprofits only

#100844-AAV1

Ready-to-use AAV1 particles produced from pAAV.CAG.GCaMP6s.WPRE.SV40 (#100844). In addition to the viral particles, you will also receive purified pAAV.CAG.GCaMP6s.WPRE.SV40 plasmid DNA. CAG-driven GCaMP6s calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

March 16, 2018

Academic Institutions and Nonprofits only

#172921-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-axon-jGCaMP8s-P2A-mRuby3 (#172921). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-jGCaMP8s-P2A-mRuby3 plasmid DNA. hSyn-driven expression of calcium sensor jGCaMP8s in axons with cytosolic expression of mRuby3. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Aug. 24, 2023

Academic Institutions and Nonprofits only

#50476-AAV1

Ready-to-use AAV1 particles produced from pAAV-CaMKIIa-hM3D(Gq)-mCherry (#50476). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hM3D(Gq)-mCherry plasmid DNA. CaMKIIa-driven hM3D(Gq) receptor with an mCherry reporter for CNO-induced neuronal activation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 8, 2025

Academic Institutions and Nonprofits only

#100853-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV.Syn.Flex.NES-jRGECO1a.WPRE.SV40 (#100853). In addition to the viral particles, you will also receive purified pAAV.Syn.Flex.NES-jRGECO1a.WPRE.SV40 plasmid DNA. Synapsin-driven, Cre-dependent GECO1a calcium sensor. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al eLife. 2016 Mar 24;5. pii: e12727. doi:

Aug. 28, 2018

Academic Institutions and Nonprofits only

#123310-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-GRAB_NEmut (#123310). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_NEmut plasmid DNA. hSyn-driven expression of GRAB-NEmut control norepinephrine sensor (does not respond to NE). These AAV preparations are suitable purity for injection into animals.

Yulong Li

Feng et al Neuron. 2019 May 22;102(4):745-761.e8. d

March 12, 2021

Academic Institutions and Nonprofits only

#105322-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-FLEX-jGCaMP7c variant 1513-WPRE (#105322). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-jGCaMP7c variant 1513-WPRE plasmid DNA. Synapsin-driven, Cre-dependent jGCaMP7c expression. jGCaMP7c exhibits high contrast between peak fluorescence and resting fluorescence. It is useful for activity imaging of large populations of densely-labeled neurons because background fluorescence from inactive neurons is reduced. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

June 13, 2019

Academic Institutions and Nonprofits only

#176753-AAV1

Ready-to-use AAV1 particles produced from AAV-mDlx-jGCaMP8f-WPRE (#176753). In addition to the viral particles, you will also receive purified AAV-mDlx-jGCaMP8f-WPRE plasmid DNA. mDlx-driven expression of ultrafast calcium sensor GCaMP8f. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Feb. 24, 2023

Academic Institutions and Nonprofits only

#221463-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe4_eGFP (#221463). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_eGFP plasmid DNA. Expression of EGFP under the control of the chandelier cell-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#105547-AAV8

Ready-to-use AAV8 particles produced from pENN.AAV.EF1a.eGFP.WPRE.rBG (#105547). In addition to the viral particles, you will also receive purified pENN.AAV.EF1a.eGFP.WPRE.rBG plasmid DNA. EF1a-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Jan. 6, 2022

Academic Institutions and Nonprofits only

#176754-AAV1

Ready-to-use AAV1 particles produced from AAV-mDlx-jGCaMP8m-WPRE (#176754). In addition to the viral particles, you will also receive purified AAV-mDlx-jGCaMP8m-WPRE plasmid DNA. mDlx enhancer-driven expression of calcium sensor GCaMP8m in GABA-ergic interneurons. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Feb. 24, 2023

Academic Institutions and Nonprofits only

#162380-AAVrg

Ready-to-use AAV Retrograde particles produced from pGP-AAV-CAG-FLEX-jGCaMP8s-WPRE (#162380). In addition to the viral particles, you will also receive purified pGP-AAV-CAG-FLEX-jGCaMP8s-WPRE plasmid DNA. CAG-driven, Cre-dependent expression of calcium sensor GCaMP8s (more sensitive). These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Zhang et al Janelia Research Campus, Online Resource

June 22, 2021

Academic Institutions and Nonprofits only

#58379-AAV8

Ready-to-use AAV8 particles produced from pAAV/D374Y-hPCSK9 (#58379). In addition to the viral particles, you will also receive purified pAAV/D374Y-hPCSK9 plasmid DNA. hAAT-driven expression of mutant (D374Y) human PCSK9. These AAV preparations are suitable purity for injection into animals.

Jacob Bentzon

Bjorklund et al Circ Res. 2014 May 23;114(11):1684-9. do

Feb. 6, 2026

Academic Institutions and Nonprofits only

#100054-AAV5

Ready-to-use AAV5 particles produced from pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 (#100054). In addition to the viral particles, you will also receive purified pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 plasmid DNA. CAG-driven, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 15, 2018

Academic Institutions and Nonprofits only

#135632-AAV9

Ready-to-use AAV9 particles produced from pAAV-S5E2-GCaMP6f (#135632). In addition to the viral particles, you will also receive purified pAAV-S5E2-GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Sept. 13, 2021

Academic Institutions and Nonprofits only

#135634-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-S5E2-ChR2-mCherry (#135634). In addition to the viral particles, you will also receive purified pAAV-S5E2-ChR2-mCherry plasmid DNA. Expression of ChR2-mCherry under the control of the E2 regulatory element. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Oct. 28, 2021

Academic Institutions and Nonprofits only

#176759-AAV9

Ready-to-use AAV9 particles produced from pZac2.1-GfaABC1D-lck-jGCaMP8f (#176759). In addition to the viral particles, you will also receive purified pZac2.1-GfaABC1D-lck-jGCaMP8f plasmid DNA. GfaABC1D-driven expression of membrane-bound calcium sensor GCaMP8f. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Feb. 24, 2023

Academic Institutions and Nonprofits only

#176758-AAV1

Ready-to-use AAV1 particles produced from AAV-EF1a-jGCaMP8s-WPRE (#176758). In addition to the viral particles, you will also receive purified AAV-EF1a-jGCaMP8s-WPRE plasmid DNA. EF1a-driven expression of calcium sensor GCaMP8s (more sensitive). These AAV preparations are suitable purity for injection into animals.

Loren Looger

July 12, 2023

Academic Institutions and Nonprofits only

#116869-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CAG-H2B-GFP (#116869). In addition to the viral particles, you will also receive purified pAAV-CAG-H2B-GFP plasmid DNA. CAG-driven expression of H2B-GFP. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Economo et al Nature. 2018 Nov;563(7729):79-84. doi: 1

Nov. 13, 2025

Academic Institutions and Nonprofits only

#99039-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CamKII-ArchT-GFP (PV2527) (#99039). In addition to the viral particles, you will also receive purified pAAV-CamKII-ArchT-GFP (PV2527) plasmid DNA. CaMKII-driven ArchT-GFP expression for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Han et al Front Syst Neurosci. 2011;5:18. Epub 201

May 15, 2019

Academic Institutions and Nonprofits only

#105547-AAVrg

Ready-to-use AAV Retrograde particles produced from pENN.AAV.EF1a.eGFP.WPRE.rBG (#105547). In addition to the viral particles, you will also receive purified pENN.AAV.EF1a.eGFP.WPRE.rBG plasmid DNA. EF1a-driven EGFP expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Oct. 18, 2021

Academic Institutions and Nonprofits only

#139505-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO-PPO-Venus (#139505). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-PPO-Venus plasmid DNA. EF1a-driven, Cre-dependent expression of Venus-tagged parapinopsin for spatiotemporal control of inhibitory GPCR signaling cascades. These AAV preparations are suitable purity for injection into animals.

Michael Bruchas

Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

Oct. 28, 2021

Academic Institutions and Nonprofits only